

Clinical Policy: Urodynamic Testing

Reference Number: CP.MP.98

Date of Last Revision: 03/23

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Urodynamic testing is an important part of the comprehensive evaluation of voiding dysfunction. The clinician must exercise clinical judgment in the appropriate selection of urodynamic tests following an appropriate evaluation and symptom characterization. The purpose of this policy is to define medical necessity criteria for commonly used urodynamic studies.

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® that urodynamic testing is **medically necessary** to assist in the diagnosis of urologic dysfunction with **any** of the following indications:
 - A. Uncertain diagnosis and inability to develop an appropriate initial treatment plan based on the clinical diagnostic evaluation;
 - B. Failure to respond to an adequate therapeutic trial;
 - C. Consideration of urologic surgical intervention, particularly if previous surgery failed or if the patient is a high surgical risk;
 - D. Presence of other comorbid conditions such as any of the following:
 1. Urinary incontinence;
 2. Persistent symptoms of difficult bladder emptying;
 3. History of previous anti-incontinence surgery or radical pelvic surgery;
 4. Symptomatic pelvic prolapse;
 5. Prostate nodule, asymmetry or other suspicion of prostate cancer;
 6. Abnormal post void residual urinalysis;
 7. Diabetes mellitus with secondary urinary incontinence;
 8. Neurological conditions affecting voiding function (neurogenic bladder) such as multiple sclerosis, Parkinson's disease, and spinal cord lesions or injury;
 9. Complex anorectal malformation.
- II. It is the policy of health plans affiliated with Centene Corporation that urodynamic testing in the following cases is considered **not medically necessary**:
 - A. More than one cystometrogram (CPT codes 51725 or 51726) or uroflowmetry study (CPT codes 51736 or 51741) per visit.
 - B. The use of any urodynamic testing for screening in asymptomatic patients, except for evaluation of neurogenic bladder or urological abnormalities associated with complex anorectal malformation.

Background

Lower urinary tract symptoms (LUTS), which include urinary incontinence, are a common and significant source of impaired quality of life and comorbidity in a large number of adults and children. LUTS is also a general term used to describe symptoms related to overactive bladder such as frequency, urgency and nocturia.²² Commonly, patients presenting with lower urinary

CLINICAL POLICY

Urodynamic Testing

tract symptoms have overlapping symptoms and conditions, making an isolated or homogeneous source of symptoms rare. Clinicians evaluating these disorders collectively utilize history, physical examination, questionnaires and testing data in the evaluation of symptoms.³ Cystometrograms, uroflowmetry, urethral pressure profile, and voiding pressure studies, among others, are used to identify abnormal voiding patterns in symptomatic patients with disorders of urinary flow. The urodynamic evaluation measures the relationship between movement and compression of bladder and abdominal pressures during the filling/storage and elimination phase of micturition.²² Each of the urodynamic studies has benefits and limitations that must be understood for each specific clinical application.

In clinical practice, the role of invasive urodynamic testing is not clearly defined. Urologists generally accept that conservative or empiric, non-invasive treatments may be instituted without urodynamic testing. Conservative treatments for urinary incontinence include pelvic muscle exercises (Kegel exercise), behavioral therapies such as bladder training and/or biofeedback, and pharmacotherapies (e.g., anticholinergic agents, musculotropic relaxants, calcium channel blockers, tricyclic antidepressants, or a combination of anticholinergic, antispasmodic medications and tricyclic antidepressants). Specifically, urge incontinence is more effectively managed with peripherally acting receptor agonists or antagonists, while stress incontinence is better controlled by pelvic muscle exercises, behavioral therapies, or corrective surgery.⁴

Urodynamic studies are indicated only after an initial evaluation is performed that, at minimum, includes an appropriate history, physical exam, and urinalysis with microscopy. Infection, if present, should be treated and effectiveness of treatment observed before further diagnostic (urodynamic) testing or other therapeutic interventions are undertaken.

Many types of urodynamic testing require urethral catheterization and include cystometry, pressure flow studies (PFS), and urethral function testing. Such testing subjects patients to risks of urethral instrumentation including infection, urethral trauma, and pain. Thus, the clinician must weigh whether urodynamic tests offer additional diagnostic benefit beyond symptom assessment, physical examination, and other diagnostic testing. A cystometrograms is used to distinguish bladder outlet obstruction from other voiding dysfunctions.

- In a simple cystometrograms (CPT code 51725), the physician inserts a pressure catheter into the bladder and using a manometer, records the pressure and flow in the lower urinary tract.
- A complex cystometrograms (CPT code 51726) uses a transurethral catheter to fill the bladder with water or gas while simultaneously obtaining rectal pressure and a transducer measures intravesical pressure.
- CPT code 51727 reports a complex cystometrograms performed in conjunction with a measurement of urethral pressure studies.
- CPT code 51728 reports a complex cystometrograms performed in conjunction with a measurement of voiding pressure studies.
- CPT code 51729 reports a complex cystometrograms performed in conjunction with a measurement of voiding pressure studies and urethral pressure studies.
- Voiding pressure studies (CPT code 51797) measure the effort the patient makes while voiding. This measurement includes the pressure required and the subsequent urine flow.

CLINICAL POLICY
Urodynamic Testing

Uroflowmetry and ultrasound post-void residual (PVR) studies may be appropriate noninvasive tests given the clinical scenario and the options for treatment.³

- In simple uroflowmetry (CPT code 51736), a stopwatch is used to record the volume of the flow of urine over time.
- Complex uroflowmetry (CPT code 51741) uses electronic equipment to measure and record the volume of urine flow over time.
- Measurement of residual urine and/or bladder emptying capacity (CPT code 51798) is accomplished using ultrasound after voiding.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2022, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. The following is a list of procedures codes for which coverage may be provided when billed with a diagnosis code(s) that supports medical necessity criteria (see list of ICD10-CM codes supporting medical necessity further below). They are current at time of review of this policy. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
51725	Simple cystometrogram (CMG) (eg, spinal manometer)
51726	Complex cystometrogram (ie, calibrated electronic equipment)
51727	Complex cystometrogram (ie, calibrated electronic equipment); with urethral pressure profile studies (i.e., urethral closure pressure profile), any technique
51728	Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique
51729	Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure) and urethral pressure profile studies (ie, urethral closure pressure profile), any technique
51736	Simple uroflowmetry (UFR) (eg, stop-watch flow rate, mechanical uroflowmeter)
51741	Complex uroflowmetry (eg, calibrated electronic equipment)
+51797	Voiding pressure studies, intra-abdominal (ie, rectal, gastric, intraperitoneal (List separately in addition to code for primary procedure)
51798	Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging

ICD-10-CM Diagnosis Codes that Support Medical Necessity

ICD-10-CM Code	Description
A18.13	Tuberculosis of other urinary organs
C70.1	Malignant neoplasm of spinal meninges
C72.0	Malignant neoplasm of spinal cord
C72.1	Malignant neoplasm of cauda equina

CLINICAL POLICY
Urodynamic Testing

ICD-10-CM Code	Description
D33.4	Benign neoplasm of spinal cord
E10.69	Type 1 diabetes mellitus with other specified complications
E11.69	Type 2 diabetes mellitus with other specified complication
G20	Parkinson's disease
G35	Multiple sclerosis
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G82.21	Paraplegia, complete
G82.22	Paraplegia, incomplete
G83.4	Cauda equina syndrome
N30.10 through N30.11	Interstitial cystitis, chronic
N30.20 through N30.21	Other chronic cystitis
N31.0 through N31.9	Neuromuscular dysfunction of bladder, not elsewhere classified
N32.0 through N32.89	Other disorders of bladder
N39.0 through N39.8	Other disorders of urinary system
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms
N40.3	Nodular prostate with lower urinary tract symptoms
N81.0 through N81.9	Female genital prolapse
Q05.0 through Q05.9	Spina bifida
Q06.0 through Q06.9	Other congenital malformations of spinal cord
Q07.00 through Q07.9	Other congenital malformations of nervous system
Q42.0 through Q42.3	Congenital absence, atresia and stenosis of large intestine
R33.8	Other retention of urine
R33.9	Retention of urine, unspecified
R35.1	Nocturia
R39.11	Hesitancy of micturition
R39.14	Feeling of incomplete bladder emptying
R39.81	Functional urinary incontinence
S14.0XXA through S14.9XXS	Injury of nerves and spinal cord at neck level
S24.0XXA through S24.9XXS	Injury of nerves and spinal cord at thorax level

CLINICAL POLICY
Urodynamic Testing

ICD-10-CM Code	Description
S34.01XA through S34.9XXS	Injury of lumbar and sacral spinal cord and nerves at abdomen, lower back and pelvis level

In addition to the above ICD-10 codes, the following additional diagnosis codes support medical necessity for CPT code 51798.

ICD-10-CM Code	Description
N13.8	Other obstructive and reflux uropathy
R33.0 through R33.9	Retention of urine
R35.0	Frequency of micturition

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed	09/15	10/15
Removed ICD-10 codes R34, R39.0 – R39.16 due to no support in literature	02/16	
References reviewed and updated Updated ICD-10 code list	10/16	10/16
References reviewed and updated. Added ICD-10-CM E10.69, E11.69, and S34.0 – S34.9XXS	09/17	10/17
References reviewed and updated. Coding reviewed.	09/18	09/18
References reviewed and updated. Added indication of complex anorectal malformation, along with accompanying diagnosis codes of Q42.0 to Q42.3. Noted in investigational statement regarding asymptomatic patients, that evaluation of suspected urological abnormalities is appropriate in the presence of complex anorectal malformation.	09/19	09/19
Added ICD-10-CM code R39.14 to support medical necessity of all procedure codes. Added ICD-10-CM code R35.1 to support medical necessity for CPT 51798.	10/19	
References reviewed and updated. Added ICD-10 codes: C70.1, C72.0, C72.1, D33.4. Replaced “members” with “members/enrollees” in all instances.	09/20	09/20
Code update: ICD-10 N40.1 and R35.1, no longer specific to 51798 and moved to list of codes that support medical necessity. Added ICD-10 codes that support medical necessity: A18.13, G82.21, G82.22, R39.11, S14.0XXA to S14.9XXS, and S24.0XXA to S24.9XXS.	10/20	
Annual review completed. Codes checked. References updated and reformatted for AMA style. Changed “Review Date” in the header to	07/21	07/21

Reviews, Revisions, and Approvals	Revision Date	Approval Date
“Date of Last Revision” and “Date” in the revision log header to “Revision Date.” Specialty review completed.		
References reviewed and updated. In 1.D.1, changed “incontinence associated with recurrent UTI” to “Urinary incontinence.” Codes checked. Updated background with no impact to policy statement.	03/22	03/22
Annual review. Added criteria I.D.5. for 4.5. Prostate nodule, asymmetry or other suspicion of prostate cancer. Moved N40.3 from ICD-10 Table 2 to ICD-10 Table 1. References reviewed and updated.	03/23	03/23

References

1. Winters JC, Dmochowski RR, Goldman HB, et al. Urodynamic studies in adults: AUA/SUFU guideline. *J Urol.* 2012;188(6 Suppl):2464-2472. doi: 10.1016/j.juro.2012.09.081
2. Shamliyan T, Wyman J, Kane RL. *Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness.* Rockville (MD): Agency for Healthcare Research and Quality (US); April 2012
3. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. *JAMA.* 2004;291(8):986-95. doi:10.1001/jama.291.8.986.
4. Cacciari LP, Dumoulin C, Hay-Smith EJ. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women: a cochrane systematic review abridged republication. *Braz J Phys Ther.* 2019;23(2):93-107. doi:0.1016/j.bjpt.2019.01.002.
5. Flesh G. Urodynamic evaluation of women with incontinence. UpToDate. www.uptodate.com. Updated April 25, 2022. Accessed February 20, 2023.
6. Anderson CA, Omar MI, Campbell SE, Hunter KF, Cody JD, Glazener CM. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev.* 2015;1(1):CD001843. 2015;1(1):CD001843. Published 2015 Jan 20. doi:10.1002/14651858.CD001843.pub5
7. Nepple KG, Cooper CS. Evaluation and diagnosis of bladder dysfunction in children. UpToDate. www.uptodate.com. Updated March 29, 2021. Accessed February 20, 2023.
8. Pang H, Dang X, Yao Z, Feng X, Wu G. Bilateral spontaneous urinary extravasation shown by computed tomography urography in a patient with benign prostatic hyperplasia. *Radiol Case Rep.* 2015;10(4):53-55. Published 2015 Sep 15. doi:10.1016/j.radcr.2015.07.001
9. Deng F, Liu X, Li Y, et al. Ureteral obstruction by prostate cancer leads to spontaneous ureteric rupture: a case report. *Int J Clin Exp Med.* 2015;8(9):16842-16844. Published 2015 Sep 15.
10. Sarmah PB, Noah A, Kelly BD, Ryan PG. Asymptomatic ureteral rupture secondary to chronic urinary retention from massive prostatic enlargement. *J Surg Case Rep.* 2015;2015(11):rjv135. Published 2015 Oct 31. doi:10.1093/jscr/rjv135
11. Mori K, Koga S, Noguchi M, Kanetake H, Suda H, Yamashita S. Spontaneous peripelvic extravasation of urine due to an inflammatory aneurysm of the abdominal aorta. *Int J Urol.* 2004;11(6):419-420. doi:10.1111/j.1442-2042.2004.00805.x
12. Schurch B, Iacovelli V, Averbeck MA, Stefano C, Altaweel W, Finazzi Agrò E. Urodynamics in patients with spinal cord injury: A clinical review and best practice paper by

- a working group of The International Continence Society Urodynamics Committee. *Neurourol Urodyn*. 2018;37(2):581-591. doi:10.1002/nau.23369
13. Clement KD, Lapitan MC, Omar MI, Glazener CM. Urodynamic studies for management of urinary incontinence in children and adults. *Cochrane Database Syst Rev*. 2013;2013(10):CD003195. Published 2013 Oct 29. doi:10.1002/14651858.CD003195.pub3
 14. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. *J Urol*. 2019;202(3):558-563. doi:10.1097/JU.0000000000000309
 15. Goossens WJ, de Blaauw I, Wijnen MH, de Gier RP, Kortmann B, Feitz WF. Urological anomalies in anorectal malformations in The Netherlands: effects of screening all patients on long-term outcome. *Pediatr Surg Int*. 2011;27(10):1091-1097. doi:10.1007/s00383-011-2959-4
 16. Sandhu JS, Breyer B, Comiter C, et al. Incontinence after Prostate Treatment: AUA/SUFU Guideline. *J Urol*. 2019;202(2):369-378. doi:10.1097/JU.0000000000000314.
 17. Foster HE, Dahm P, Kohler TS, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. *J Urol*. 2019;202(3):592-598. doi:10.1097/JU.0000000000000319
 18. Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. *J Urol*. 2020;204(4):799-804. doi:10.1097/JU.0000000000001298
 19. Sandhu JS, Breyer B, Comiter C, et al. Incontinence after Prostate Treatment: AUA/SUFU Guideline. *J Urol*. 2019;202(2):369-378. doi:10.1097/JU.0000000000000314.
 20. Local coverage determination: urodynamics (L34056). Centers for Medicare and Medicaid Services Web site. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34056&ver=24&>. Published October 1, 2015 (revised October 6, 2022). Accessed February 22, 2023.
 21. Local coverage determination: urodynamics (L33576). Centers for Medicare and Medicaid Services Web site. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33576&ver=23&keywordtype=starts&keyword=urod&bc=0>. Published October 1, 2015 (revised October 24, 2019). Accessed February 22, 2023.
 22. McVary KT. Lower urinary tract symptoms in males. UpToDate. www.uptodate.com. Updated September 26, 2023. Accessed February 20, 2023.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

CLINICAL POLICY

Urodynamic Testing

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

CLINICAL POLICY

Urodynamic Testing

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.